NASDAQ$PAYS

Paysign Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Paysign's Q4 2021 financial results were reported, showing improved load volumes and spending trends approaching pre-pandemic levels.

Paysign reported positive Q4 results with improving revenues, income from operations, EBITDA, and adjusted EBITDA. The balance sheet also improved sequentially. The company is optimistic about growth prospects in plasma, pharma, and other prepaid businesses.

  • Load volumes and spending trends improved, nearing pre-pandemic levels.
  • Strategic priorities are being executed, with new deals in plasma and pharma.
  • The team and technology are being built out to handle future opportunities.
  • Revenues, income from operations, EBITDA, and adjusted EBITDA all improved both sequentially and year over year.

Headline financials

Total Revenue

$8.77M

Previous: $7.25M+20.9%
EPS (adj)

$0.00

Previous: $0.01-79.9%
Capital Expenditures

$139K

Previous: $287K-51.5%
Free Cash Flow

-$942K

Previous: $910K-203.5%
Net Income

$105K

Previous: -$4.31M+102.4%
Operating Income

$103K

Previous: -$658K+115.6%
Gross Profit

$4.76M

Previous: $3.71M+28.2%
Cash & Equivalents

$7.4M

Previous: $7.83M-5.5%
Total Assets

$84.1M

Previous: $67.8M+23.9%
Stock-Based Comp

$500K

Previous: $848K-41.0%

Revenue & EPS history

Paysign · Revenue · Quarterly

$8.77M

Q4 2021+20.9%vs Q4 2020
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Forward guidance

For the full year 2022, Paysign expects total revenue to be in the range of $35.25 million to $38.35 million, reflecting growth of 20% to 30%, with plasma making up approximately 90% of total revenue. Pharma revenue is expected to be relatively flat year over year as the loss of programs and settlement income in 2021 are offset with new pharma copay programs. Adjusted EBITDA is expected to at least double to $4.0 million over 2021’s adjusted EBITDA of $2.0 million.

Tailwinds

  • Total revenue is expected to grow by 20% to 30%.
  • Plasma is expected to make up approximately 90% of total revenue.
  • Adjusted EBITDA is expected to at least double to $4.0 million.
  • Full year gross profit margins are expected to be approximately 50.0% to 52.5%.
  • Company continues to make investments in people and technology.

Headwinds

  • Pharma revenue is expected to be relatively flat year over year.
  • Loss of programs and settlement income in 2021 are offset with new pharma copay programs.
  • Operating expenses are expected to increase to approximately $20.0 million.
  • Higher costs in insurance, travel and entertainment and other inflationary pressures.
  • Q1 2022 operating results to be somewhat skewed relative to historical Q1 results.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+16.2%

Avg return

Earnings day

+4.1%

Avg return

5 days after

+7.8%

Avg return

30 days after

44%

27 / 61 earnings

Positive

+900.0%

Q3 2011

Best reaction

-29.6%

Q4 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+37.3%-4.3%
Q1 2026-12.6%-12.0%+4.8%
Q3 2025+0.2%-8.8%+0.4%
Q2 2025+13.0%+4.2%+0.6%
Q1 2025+3.0%+22.9%+81.9%
Q4 2024-8.5%-14.5%-8.1%
Q3 2024+10.9%+8.7%-7.9%
Q2 2024-6.7%-14.4%-9.2%
Q1 2024-0.4%+5.4%-7.6%
Q4 2023+20.5%+10.2%+31.9%
Q3 2023+18.1%+21.6%+18.1%
Q2 2023+6.4%+8.6%+16.0%
Q1 2023-1.8%-4.5%-20.7%
Q4 2022+4.2%+7.6%+0.3%
Q3 2022-10.4%+8.9%+16.5%
Q2 2022+7.4%+15.3%+33.5%
Q1 2022-26.2%-20.2%-2.4%
Q4 2021-6.6%-16.6%-21.4%
Q3 2021-9.0%-14.6%-32.8%
Q2 2021-2.4%+5.6%+16.7%
Q1 2021-11.4%-10.8%+0.0%
Q4 2020+11.7%+5.1%+0.8%
Q3 2020-26.8%-20.6%-7.7%
Q2 2020-18.9%-30.5%-45.3%
Q1 2020-5.5%-13.0%-0.4%
Q4 2019+27.3%+82.9%+102.7%
Q3 2019+13.2%+17.1%+3.9%
Q2 2019+2.5%+6.3%+2.7%
Q1 2019-11.7%-6.7%+18.2%
Q4 2018-1.7%-7.5%-1.0%
Q3 2018-0.5%-1.6%-6.3%
Q2 2018+10.1%+2.7%-2.7%
Q1 2018-0.9%+18.8%+23.1%
Q4 2017+19.0%+20.6%+44.3%
Q3 2017+7.9%+19.3%+15.8%
Q2 2017+2.8%+9.4%+0.0%
Q1 2017-8.7%-6.5%-6.5%
Q4 2016+4.7%+0.0%+0.0%
Q3 2016+34.9%+73.7%+73.7%
Q2 2016+0.0%-5.0%-20.0%
Q1 2016-23.2%
Q4 2015-29.6%
Q3 2015-12.0%
Q2 2015+6.3%
Q1 2015+4.3%
Q4 2014+71.2%
Q2 2014-16.7%
Q1 2014+0.0%
Q4 2013+23.4%
Q3 2013-17.9%
Q2 2013-16.6%
Q4 2012-4.3%
Q1 2013-4.3%
Q3 2012+18.5%
Q2 2012+0.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+900.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010+5.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro